About Protagonist Therapeutics
Protagonist Therapeutics is a company based in Milpitas (United States) founded in 2001.. Protagonist Therapeutics has raised $67 million across 10 funding rounds from investors including HHS, RA Capital and Canaan. The company has 126 employees as of December 31, 2024. Protagonist Therapeutics offers products and services including Icotrokinra and Hepcidin Mimetic. Protagonist Therapeutics operates in a competitive market with competitors including Aclaris Therapeutics, OMass Therapeutics, Prometheus Biosciences, Enterome and Kanvas Biosciences, among others.
- Headquarter Milpitas, United States
- Employees 126 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Protagonist Therapeutics, Inc.
-
Annual Revenue
$434.43 M624.05as on Dec 31, 2024
-
Net Profit
$275.19 M0as on Dec 31, 2024
-
EBITDA
$255.81 M0as on Dec 31, 2024
-
Total Equity Funding
$67 M (USD)
in 10 rounds
-
Latest Funding Round
-
Investors
HHS
& 11 more
-
Employee Count
126
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Protagonist Therapeutics
Protagonist Therapeutics is a publicly listed company on the NASDAQ with ticker symbol PTGX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Protagonist Therapeutics
Protagonist Therapeutics offers a comprehensive portfolio of products and services, including Icotrokinra and Hepcidin Mimetic. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational therapy targeting IL-23 receptor for inflammatory diseases
Potential treatment for blood disorders through peptide innovation
Unlock access to complete
Unlock access to complete
Funding Insights of Protagonist Therapeutics
Protagonist Therapeutics has successfully raised a total of $67M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Last Round
-
First Round
First Round
(19 Sep 2006)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2023 | Amount | Post-IPO - Protagonist Therapeutics | Valuation |
investors |
|
| Oct, 2019 | Amount | Debt – Conventional - Protagonist Therapeutics | Valuation |
investors |
|
| Sep, 2018 | Amount | Grant - Protagonist Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Protagonist Therapeutics
Protagonist Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, RA Capital and Canaan. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Canaan is recognized as an early-stage venture capital firm.
|
Founded Year | Domain | Location | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location | |
|
Early-stage life sciences investments are targeted in the healthcare sector.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Protagonist Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Protagonist Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Protagonist Therapeutics Comparisons
Competitors of Protagonist Therapeutics
Protagonist Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, OMass Therapeutics, Prometheus Biosciences, Enterome and Kanvas Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
|
| domain | founded_year | HQ Location |
Drugs for gastrointestinal diseases are developed using clinical biobanks.
|
|
| domain | founded_year | HQ Location |
Developer of immunomodulators for cancer and auto-immune diseases
|
|
| domain | founded_year | HQ Location |
Imaging solutions for microbial research and infectious diseases are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Protagonist Therapeutics
Frequently Asked Questions about Protagonist Therapeutics
When was Protagonist Therapeutics founded?
Protagonist Therapeutics was founded in 2001 and raised its 1st funding round 5 years after it was founded.
Where is Protagonist Therapeutics located?
Protagonist Therapeutics is headquartered in Milpitas, United States. It is registered at Milpitas, California, United States.
Who is the current CEO of Protagonist Therapeutics?
Dinesh Patel is the current CEO of Protagonist Therapeutics.
Is Protagonist Therapeutics a funded company?
Protagonist Therapeutics is a funded company, having raised a total of $67M across 10 funding rounds to date. The company's 1st funding round was a Grant of $1.45M, raised on Sep 19, 2006.
How many employees does Protagonist Therapeutics have?
As of Dec 31, 2024, the latest employee count at Protagonist Therapeutics is 126.
What is the annual revenue of Protagonist Therapeutics?
Annual revenue of Protagonist Therapeutics is $434.43M as on Dec 31, 2024.
What does Protagonist Therapeutics do?
Protagonist Therapeutics was founded in 2001 and is headquartered in Milpitas, United States. Focus is placed on the biotechnology sector, where oral peptide therapeutics are developed for gastrointestinal conditions such as inflammatory bowel diseases and irritable bowel syndrome. The pipeline includes PTG-100, an α4β7 integrin antagonist, and IL-23 receptor antagonists for IBD treatment. Additional efforts target IL-6 as an anti-inflammatory agent and hepcidin mimetics for iron overload disorders.
Who are the top competitors of Protagonist Therapeutics?
Protagonist Therapeutics's top competitors include Aclaris Therapeutics, Prometheus Biosciences and OMass Therapeutics.
What products or services does Protagonist Therapeutics offer?
Protagonist Therapeutics offers Icotrokinra and Hepcidin Mimetic.
Is Protagonist Therapeutics publicly traded?
Yes, Protagonist Therapeutics is publicly traded on NASDAQ under the ticker symbol PTGX.
Who are Protagonist Therapeutics's investors?
Protagonist Therapeutics has 12 investors. Key investors include HHS, RA Capital, Canaan, National Heart, Lung, and Blood Institute, and Adage Capital Management.
What is Protagonist Therapeutics's ticker symbol?
The ticker symbol of Protagonist Therapeutics is PTGX on NASDAQ.